Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Leukemia through trial conditions or approval indications mapped to it or to one of its descendant entities.
26 drugs · 850 active trials
42 drugs · 1,288 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 2 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tandutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-05 |
| Tislelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jun 29, 2016 |
| Vismodegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-02 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-03 |
| Axitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-12 |
| Bafetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-07 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-01 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 3, 2015 |
| Elotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 10, 2013 |
| Eprenetapopt | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 18, 2017 |
| Fadraciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 2, 2019 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-10 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-06 |
| Sonidegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-05 |
| Trastuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-11 |
| Aminolevulinic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-02 |
| Birabresib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-01 |
| Camonsertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 23, 2022 |
| CHOP Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-06 |
| Crizotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-12 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 16, 2013 |
| Estramustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-09 |
| Ganetespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-04 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-08 |
| Interferon Beta-1a | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2025 |
| Megestrol | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-06 |
| MEK-1/MEKK-1 Inhibitor E6201 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 10, 2015 |
| MUC1-targeted Peptide GO-203-2C | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-09 |
| Pixantrone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-03 |
| Quarfloxin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-06 |
| Ridaforolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-06 |
| Sapanisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 6, 2017 |
| Sotrastaurin Acetate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 12, 2015 |
| Sulindac | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-01 |
| Therapeutic Glucocorticoid | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-10 |
| Uprosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-10 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-12 |
| Vatalanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-12 |
| Vinblastine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 15, 2013 |
| Entrectinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Cemiplimab | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 4, 2017 |
| Nintedanib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 14, 2018 |
| Odronextamab | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 14, 2025 |
| Pemigatinib | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 14, 2021 |
| Rezatapopt | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 30, 2025 |
| Ribociclib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2019 |
| Roflumilast | Phase 1 | Early Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 24, 2018 |
| Tazemetostat | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 28, 2023 |
| Regorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Apr 17, 2017 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-11 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.